- Home
- PMX vs CRDF Comparison
PMX vs CRDF Comparison
Compare PMX & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMX
- CRDF
- Stock Information
- Founded
- PMX 2002
- CRDF 1999
- Country
- PMX United States
- CRDF United States
- Employees
- PMX N/A
- CRDF N/A
- Industry
- PMX Trusts Except Educational Religious and Charitable
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PMX Finance
- CRDF Health Care
- Exchange
- PMX Nasdaq
- CRDF Nasdaq
- Market Cap
- PMX 243.2M
- CRDF 240.2M
- IPO Year
- PMX N/A
- CRDF N/A
- Fundamental
- Price
- PMX $7.27
- CRDF $3.45
- Analyst Decision
- PMX
- CRDF Strong Buy
- Analyst Count
- PMX 0
- CRDF 3
- Target Price
- PMX N/A
- CRDF $10.33
- AVG Volume (30 Days)
- PMX 101.5K
- CRDF 1.4M
- Earning Date
- PMX 01-01-0001
- CRDF 02-27-2025
- Dividend Yield
- PMX 5.28%
- CRDF N/A
- EPS Growth
- PMX N/A
- CRDF N/A
- EPS
- PMX N/A
- CRDF N/A
- Revenue
- PMX N/A
- CRDF $688,000.00
- Revenue This Year
- PMX N/A
- CRDF $25.03
- Revenue Next Year
- PMX N/A
- CRDF N/A
- P/E Ratio
- PMX N/A
- CRDF N/A
- Revenue Growth
- PMX N/A
- CRDF 49.57
- 52 Week Low
- PMX $6.09
- CRDF $1.44
- 52 Week High
- PMX $8.47
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- PMX 40.85
- CRDF 45.05
- Support Level
- PMX $7.09
- CRDF $3.33
- Resistance Level
- PMX $7.48
- CRDF $4.89
- Average True Range (ATR)
- PMX 0.07
- CRDF 0.31
- MACD
- PMX 0.01
- CRDF -0.15
- Stochastic Oscillator
- PMX 46.15
- CRDF 10.56
About PMX PIMCO Municipal Income Fund III of Beneficial Interest
PIMCO Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as transportation, healthcare, and others.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").